Novartis Strikes Deal with Argo Biopharma for Global Rights to siRNA Drug Candidates
Argo Biopharma, a Shanghai-based developer of small interfering RNA (siRNA) drugs, has secured a licensing...
Argo Biopharma
Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round
Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million)...